Understanding how a process called acetylation affects HIV
Role of Factor Acetylation in the Regulation of HIV Transcription
['FUNDING_R37'] · J. DAVID GLADSTONE INSTITUTES · NIH-11064062
This research explores how a natural process in our bodies, called acetylation, can help us find new ways to control HIV and potentially achieve a functional cure.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | J. DAVID GLADSTONE INSTITUTES (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11064062 on ClinicalTrials.gov |
What this research studies
We are looking into how a process called factor acetylation influences HIV, particularly how the virus hides in the body and then reactivates. Our goal is to understand the unique role of acetylation in establishing, maintaining, and reactivating latent HIV infection. We believe that specific proteins, BRD4 and RPRD1, which 'read' these acetylation marks, are key to controlling hidden HIV. By understanding these mechanisms, we hope to identify new drug targets that could lead to more effective treatments for HIV.
Who could benefit from this research
Good fit: This foundational research is relevant to anyone living with HIV, as it seeks to understand the basic mechanisms of viral latency and potential cures.
Not a fit: Patients without HIV would not directly benefit from this specific research, as it focuses on the biology of the HIV virus.
Why it matters
Potential benefit: If successful, this research could lead to new drug targets that help achieve a functional cure for HIV, allowing patients to live without active virus or daily medication.
How similar studies have performed: The concept of targeting factor acetylation for HIV treatment is a promising area, and this work aims to fully explore its potential as a drug target.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- J. DAVID GLADSTONE INSTITUTES — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OTT, MELANIE MARIA — J. DAVID GLADSTONE INSTITUTES
- Study coordinator: OTT, MELANIE MARIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome Virus